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Abstract
BACKGROUND: Recent clinical trials have shown that the adaptive drug therapy can be more efficient
than a standard MTD-based policy in treatment of cancer patients. The adaptive therapy paradigm is not based
on a preset schedule; instead, the doses are administered based on the current state of tumor. But the adaptive
treatment policies examined so far have been largely ad hoc. In this paper we propose a method for systematically
optimizing the rules of adaptive policies based on an Evolutionary Game Theory model of cancer dynamics.
METHODS: Given a set of treatment objectives, we use the framework of dynamic programming to find the
optimal treatment strategies. In particular, we optimize the total drug usage and time to recovery by solving a
Hamilton-Jacobi-Bellman equation based on a mathematical model of tumor evolution.
RESULTS: We compare adaptive/optimal treatment strategy with MTD-based treatment policy. We show
that optimal treatment strategies can dramatically decrease the total amount of drugs prescribed as well as increase
the fraction of initial tumour states from which the recovery is possible. We also examine the optimization trade-
offs between the total administered drugs and recovery time.
CONCLUSIONS: The adaptive therapy combined with optimal control theory is a promising concept in
the cancer treatment and should be integrated into clinical trial design.
Keywords: adaptive therapy; optimal treatment policy; evolutionary game theory; Hamilton-Jacobi-Bellman
equation; heterogeneity
1 Introduction
Intratumoral heterogeneity is being increasingly recognized as a cause of metastasis, progression and resistance
to therapy1. While genetic instability, a hallmark of malignancy2, can result in this heterogeneity, it is being
increasingly understood that eco-evolutionary factors, like selection and clonal interference, can also drive and
maintain it3,4.
While sequencing technologies have enabled increasingly in-depth quantitative understanding of the genetic
heterogeneity, relatively little experimental work has sought to directly quantify the eco-evolutionary interactions
involved. As more studies come to light showing the efficacy of treatments based on eco-evolutionary trial designs,
this lack of quantification is coming into focus.
In line with standard, cell-autonomous growth-based theories, conventional chemotherapy is given to patients
at the maximum tolerated doses (MTD): the highest doses that most patients can safely tolerate. Although
the MTD-based chemotherapy offers advantages in survival compared to no therapy, cures remain elusive, and
side effects can be severe. In addition to the toxicity, it is known that relapse is nearly inevitable due to the
emergence of therapeutic resistance: a process driven by Darwinian evolutionary dynamics in which the MTD-
based chemotherapy kills off the chemotherapy-sensitive cells and chemo-refractory cells eventually dominate in
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the tumor. While it is unknown whether these resistant cells are present before therapy, or acquire resistance
mutations during therapy, it is the process of variation and selection under standard therapy that drives the
inevitable failure in the patient.
Metronomic chemotherapy has been proposed as a possible alternative to the MTD strategy5,6. Metronomic
chemotherapy is given in an on/off fashion at frequent time intervals according to a set periodic schedule. The idea
behind this method is to give less overall therapy, thereby increasing tolerability, and allowing time for therapy
sensitive cells to regrow, allowing for resensitization of the tumor. Frustratingly, the results of clinical trials of
metronomic chemotherapy have been “variable”7 and many of them have not demonstrated significant efficacy8–10
as compared to standard therapy. Recent studies argue that metronomic chemotherapy highly depends on timing,
and the right scheduling can improve the results of its usage11.
Based on the hypothesis that disease dynamics depend on the evolution of tumor heterogeneity as modulated
by competition between subtypes, the idea of using adaptive therapy (AT) has been proposed12. AT is much
like metronomic therapy, with an important difference. AT administers doses of therapy according to the current
state of tumor growth and its anticipated evolutionary changes (trajectory). These can be estimated using direct
(e.g., taking biopsies) or indirect (e.g., antigen testing, mathematical modeling) methods. Therefore, unlike the
MTD-based or metronomic protocols, AT does not have preset schedule and it adjusts the doses and timing before
a tumor becomes chemotherapy-resistant, prolonging time to this event. Recently, the adaptive strategies have
shown promise in pre-clinical trials of breast cancer13 and a phase 2 clinical trial in metastatic castrate-resistant
prostate cancer14.
These two recent successes13,14 in adaptive therapy have been based on mathematical modeling of tumor
evolution under therapy using a dynamical systems approach based on Evolutionary Game Theory (EGT)15,16.
This formalism explicitly considers interactions between sub-populations and models their fitness in frequency
dependent terms. EGT has been used to theoretically consider many scenarios in cancer before, including ther-
apy scheduling and timing in prostate cancer14,17–19; the use of tumor microenvironment targeting therapy in
glioblastoma20; the trade-off between healthy tissue and cancer in multiple myeloma21,22; and drug resistance in
general23–25. These theoretical studies, combined with the recent empiric realizations, suggest significant oppor-
tunities to improve therapy by using this evolutionarily enlightened approach. Nevertheless, therapeutic decisions
in general practice are currently not based on this knowledge and continue to use the MTD paradigm.
Assuming that an oncologist has perfect information about the current state of a tumor, and a faithful
mathematical model that can predict its trajectory (these, of course, are very strong assumptions), it is not
clear how he/she should adjust the schedule and doses. Based on a stage of the disease and patient’s needs, the
therapy can have different final goals: maximization of patient’s duration of life, ensuring the best possible quality
of the rest of life, decreasing probability of new metastases appearing, decreasing time/cost of the treatment,
etc.. Unfortunately, an oncologist can usually only focus on one or two of these goals, having some reasonable
constraints on the secondary parameters. Thus, an important step toward optimizing AT is to define an objective
of the therapy and “translate” it into mathematical language. The next step is to quantify how good each
particular strategy is with respect to that chosen objective. Optimizing this objective is a mathematical goal
which can be addressed by the tools of optimal control theory.
Optimal control theory, a branch of mathematics typically applied to problems in engineering, can be applied
to a wide class of problems arising in oncology26. The first application of optimal control theory in cancer was
done by Swan and Vincent27 who found the optimal treatment strategy for multiple myeloma with the objective
to minimize the total amount of drugs used applying the Pontryagin Minimum Principle (PMP)28. Since then,
others have used the PMP to different optimal cancer treatment problems: a chemotherapy optimization under
evolving drug resistance29–31, optimal scheduling of a vessel disruptive agent32, MAPK inhibitors33 input in
cancer treatment, minimization amount of drugs prescribed in tumorCimmune model34, finding compromise
between drug toxicity and tumor repression for the myeloma bone disease35, and many others.
While these approaches have offered benefits in their ability to formally optimize problems written as dynamical
systems, the PMP method has several limitations. First, PMP yields only a necessary condition for an optimum,
and any locally optimal trajectory of the control system satisfies PMP. Local optimality means that the trajectory
is optimal when comparing it with its small perturbations, but there may well be a different trajectory that is
even better (globally optimal, compared with all possible trajectories). Secondly, PMP provides a time-dependent
(open-loop) control: given an initial state, the method provides an optimal treatment strategy as a function of
time – therefore a treating oncologist has to follow it regardless of the changing state of the tumor. However,
if the underlying model has been perturbed or includes some noise (like a tumor acquiring mutations, say), the
control cannot adapt to these unexpected changes.
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A different approach to analysis of an optimal control problem is a feedback (closed-loop) control point of
view. Using the Hamilton-Jacobi-Bellman (HJB) equations, one can obtain controls that depend on the current
state of the dynamical system (current distribution of sub-populations of cancer cells) rather than only the current
time36,37. In this case, the treating oncologist’s decisions can be adjusted if something unexpected has happened
with the trajectory. Moreover, the HJB equations guarantees that the resulting treatment feedback strategies are
globally optimal. Despite these advantages of the HJB over PMP method, there are few works38,39 which use the
feedback control paradigm to find an optimal treatment strategy.
Here, we apply the HJB approach to solve for optimal treatment strategies for a model of lung cancer proposed
by Kaznatcheev and colleagues40. In that paper the authors introduce an evolutionary game (system of replicator-
type equations) that models the dynamics of three sub-populations of tumor cells. The article highlights the
importance of a good scheduling in the polyclonal regime, when the game has cyclic dynamics. The article has
an example of two different scheduling strategies with the same set of initial parameters that lead the system to
opposite outcomes: putative recovery, versus putative death of a patient. While several qualitatively different
treatment schedules are presented, optimal therapy is not discussed. Given the growing interest in EGT in clinical
applications14 and recent work connecting these models using direct in vitro parameterization41, we believe the
optimization of therapies based on such models will become increasingly important and the HJB-based approach
will be used far more often in the future.
2 Methods
In this article we focus on a model of cancer evolution that has been proposed in Kaznatcheev et al.40 and
summarized in Box 1. This model considers interactions between three different sub-populations of cancer cells
playing a modified version of the public goods social dilemma: glycoltyic cells (GLY), vacscular overproducers
(VOP) and cells called defectors (DEF) which use both strategies to “cheat” on the others. GLY cells are anaerobic
and produce lactic acid. Both VOP and DEF cells are aerobic. In addition, VOP cells spend extra energy to
produce VEGF (a protein that improves the vasculature, benefiting both VOP and DEF). Based on the replicator
model from EGT15,16 summarized in equations (1) and (3), the evolution of the tumor is described by tracking the
changing proportions of GLY, VOP and DEF cells in the full population. The patient is viewed as recovered when
the GLY proportion falls below some low threshold rb. (Below this recovery barrier, the validity of replicator-based
model is harder to justify and we assume that the GLY cells are essentially extinct.) Conversely, we assume that
GLY cells suppress other tumor cells and a patient dies if the total proportion of aerobic cells (VOP and DEF
sub-populations combined) falls below some low threshold (a failure barrier) fb.
For a range of parameter values (4), this model predicts a heterogeneous regime∗ in cancer evolution with
coexistent and oscillating proportions of GLY, VOP, and DEF. Without any treatment, these sub-populations
follow cyclic dynamics and a patient never recovers; see Figure 1(a).
Following Section 4.1. in Kaznatcheev et al.40 we consider a cell-type-targeting therapy that preferentially
penalizes the fitness of GLY cells; see formula (7) in Box 2. During the treatment, a doctor defines the timing of
therapy and its intensity. This time-dependent intensity d(t) can vary between 0 (no therapy) and dmax > 0 (the
maximum tolerated dose, MTD). Two extreme case (d(t) = 0 versus d(t) = dmax for all times t) are illustrated in
Figures 1(a) and 1(b) respectively. In the latter case, GLY cells become extinct and the patient recovers quickly,
however it is natural to ask whether this treatment strategy is optimal in some sense (i.e. could the recovery be
much delayed if the patient received therapy less often or at a lower intensity?). In the following section we will
show that the MTD-based treatment can lead to an avoidably high cumulative amount of therapy (see Figure 2(c)
or might even fail to achieve a recovery in situations where AT-based treatment would otherwise have succeeded
(see Figure 6), much like the early results from Zhang et al. in metastatic prostate cancer14.
∗Other tumor regimes (fully angiogenic and glycolyctic) also exist outside of this parameter range. They are less interesting from the
point of view of treatment strategies, but we still consider them for the sake of completeness in Section 6.3 of Supplementary Materials.
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Box 1: Mathematical model of the cancer sub-populations evolution
Subpopulation Proportions:
(xG, xD, xV )
for GLY, DEF, and VOP respectively.
Note: xG + xD + xV = 1.
Relative Subpopulation Fitness: (ψG, ψD, ψV )
defined in Materials and Methods of Kaznatcheev et al.40).
Full Population Averaged Fitness:
< ψ >:= xGψG + xDψD + xV ψV .
Replicator equations to model the evolution of sub-populations:
˙xD = xD(ψD− < ψ >)
x˙G = xG(ψG− < ψ >)
˙xV = xV (ψV− < ψ >)
(1)
Transformation/Reduction to a 2D system:
{
q =
xV
x
V
+x
D
p = xG
or

xD = (1− q)(1− p)
xG = p
xV = (1− p)q
(2)
Equivalent dynamics of (1) in reduced coordinates (see Appendix B in40):
q˙ = q(1− q)
(
bv
n+1
n∑
k=0
pk − c
)
p˙ = p(1− p)
(
ba
n+1
− (bv − c)q
) (3)
Parameters:
• ba, the benefit per unit of acidification;
• bv, the benefit from the oxygen per unit of vascularization;
• c, the cost of production VEGF;
• n, the number of glycolytic (GLY) cells in the interaction group.
Conditions for homogeneous center equilibrium and periodic oscillations:
ba
n+ 1
< bv − c < cn. (4)
Process terminates as soon as either{
p(t) < rb, if therapy succeeds;
p(t) > 1− fb, if therapy fails.
(5)
Terminal set:
∆ =
{
(q, p) ∈ [0, 1]× [0, 1] : p < rb or p > 1− fb
}
. (6)
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(a) (b)
Figure 1: A comparison of two possible constant treatment scenarios starting from an initial state (xD, xG, xV ) =
(0.04, 0.9, 0.06): (a) without any therapy; (b) with the MTD-based therapy.
Top row: phase portraits of corresponding vector fields (shown by gray arrows) on a GLY-VOP-DEF triangle with illustra-
tive trajectories. Blue background and green reference trajectory – no therapy at all. Yellow background and red reference
trajectory – MTD-based therapy at all times. Dash light blue and gray lines separate the recovery zone (bottom) and the
failure zone (top) respectively. Black cross – termination due to crossing the recovery barrier.
Bottom row: evolution of sub-populations with respect to time based on the reference trajectories above. Green time range –
no therapy. Pink time range – MTD-based therapy. Black cross – termination due to crossing the failure or recovery barrier
by GLY cells. Note the different scaling of the time axis.
Parameters: Following Figure 2 in40, ba = 2.5, bv = 2, c = 1, n = 4 and dmax = 3 for (b). The recovery and failure barriers
are rb = fb = 10
−1.5.
Box 2: Evolution dynamics with control on therapy intensity
Time-dependent intensity of GLY-targeting therapy: d : R+ → [0, dmax].
Evolutionary dynamics as a controlled system:
q˙(t) = q(t)
(
1− q(t)
)(
bv
n+1
n∑
k=0
pk(t)− c
)
,
p˙(t) = p(t)
(
1− p(t)
)(
ba
n+1
− (bv − c)q(t)− d(t)
)
;
q(0) = q0, p(0) = p0.
(7)
One natural objective function to minimize is the total amount of therapy administered over the course
of treatment (which in this case could be a surrogate for both toxicity and cost). This can be quantified as
D =
T∫
0
d(t)dt, where the total time of treatment T is dependent on the initial cancer subpopulation fractions and
on our chosen therapy policy d(·). However, this objective is problematic for two reasons. First, the minimum
of D is clearly attained without any therapy (taking d(t) ≡ 0 implies D = 0 and T = +∞), even though the
dynamics become cyclic and the recovery is never achieved. Second, if we constrain our minimization to only those
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d(·) that lead to recovery, an optimal treatment policy does not exist. Instead, there is a sequence of treatment
policies that lead to successively smaller d values but with an unbounded increase in corresponding treatment
times T . The idea of such policies is simple: travel along the therapy-free trajectories of Figure 1(a) for most of
the time, but use short bursts of therapy only when the drugs are most effective. To approach the optimally small
d, one would need to use shorter and shorter bursts, resulting in policies that are hard to implement in practice
and would require unrealistically long treatment times T , but would yield a situation like a chronic disease, where
while the tumor is never cured, it is always controlled.
In order to get a meaningful optimal policy we will penalize the treatment time by a time penalty σ > 0. The
total time spent on the treatment, including time when a patient skips the doses, is an important factor by itself.
Much longer time spent on a treatment causes worse quality of life and additional costs for a patient. Therefore,
our objective is to minimize the sum of a therapy cost D and a treatment time cost σT , while guaranteeing the
treatment results in recovery. For every choice of σ > 0, the resulting treatment policies are thus Pareto-optimal
with respect to D and T .
In this paper we consider an objective function that is equal to
T∫
0
d(t) dt + σT , if a patient recovers, and is
equal to +∞ otherwise. The value function, u, is defined as the minimum of this objective function (over the set
of treatment policies), and any policy d(·) that realizes this minimum is called optimal.
Due to the structure of this optimization problem, one can show that virtually all optimal treatment policies
are bang-bang: at any given time t, they either administer therapy at MTD-rate (d(t) = dmax) or administer
no drugs at all (d(t) = 0); see Section 6.1 in Supplementary Materials. For such policies, the objective function
becomes a weighted sum of the total therapy time T˜ (when d(t) ≡ dmax) and the total treatment time T , with
dmax and σ as the corresponding weights. Moreover, this allows for a simple visual representation of any such
policy: splitting the full state space into two parts (MTD dynamics vs. no-therapy dynamics), shown in yellow
and blue respectively in all figures throughout this paper, and simplifies application of therapy into something
familiar to clinicians: on or off.
3 Results
3.1 Quantifying the benefits of optimal treatment strategies
In this section we apply the optimal control theory to an example considered in Kaznatcheev et al.40. The details
of the optimal control problem formulation are summarized in Box 3. We take the same model parameters as in
Figure 2 of Kaznatcheev et al.40: ba = 2.5, bv = 2, c = 1, n = 4, strength of MTD dmax = 3, and initial state
(q0, p0) = (0.6, 0.9), which by formula (2) is equivalent to (xD, xG, xV ) = (0.04, 0.9, 0.06). We also use σ = 0.01
to incorporate a time-penalty absent in the original model. We take rb = fb = 10
−1.5 as recovery and failure
barriers†
In Figure 2 we compare the treatment cost (10) and treatment time (8) of trajectories corresponding to four
different treatment strategies.
The first two strategies we consider are similar to those modeled in Kaznatcheev et al.40: 2(a) is an example
of a bad policy that may cause a failure by stopping the therapy prematurely, while 2(b) is a good policy based
on ad-hoc adjustment of the start time for the therapy. We also illustrate a “MTD-based”’ policy 2(c), which is
analogous to the standard of care using MTD as long as possible. Even though both 2(b) and 2(c) lead to recovery,
neither of these is optimal (with the MTD-based approach resulting in excessive amount of drugs, captured by
the higher cost). The policy minimizing our objective function can be found by solving the HJB equation; we
illustrate it in 2(d).
†This change in parameter values is meant to decrease the computational cost of our numerical approach (see section 6.2 in Supple-
mentary Materials.) The original rb = fb = 10
−4 from Kaznatcheev et al.40 would require computations on a finer mesh.
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Box 3: Objective function
Terminal time (or the total treatment time):,
T (q0, p0, d(·)) = min
{
t ∈ R+ | (q(t), p(t)) ∈ ∆, q(0) = q0, p(0) = p0
}
. (8)
If the system never gets to the terminal set, we assume that T (q0, p0, d(·)) = +∞.
Terminal cost function is g(q, p) : ∆→ {0,+∞} s.t.
g(q, p) =
{
+∞, if p > 1− fb,
0, otherwise.
(9)
Let T := T (q0, p0, d(·)) be the terminal time.
Treatment cost (objective) function:
J(q0, p0, d(·)) =
T∫
0
(d(s) + σ)ds+ g
(
q
(
T
)
, p
(
T
))
. (10)
J is finite if the system (7) terminates at the recovery barrier, and is infinite otherwise (i.e., if the system terminates
at the failure barrier or does not terminate at all).
Value function:
u(q0, p0) = inf
d(·)
J(q0, p0, d(·)) (11)
can be found by solving Hamilton-Jacobi-Bellman (HJB) PDE:
min
d∈[0,dmax]
{
∇u(q, p) ·
(
q˙(q, p, d)
p˙(q, p, d)
)
+ d+ σ
}
= 0, (q, p) ∈ ([0, 1]× [0, 1])/∆. (12)
The boundary conditions of HJB equation:{
u(q, p) = 0, if p < rb;
u(q, p) = +∞, if p > 1− fb.
(13)
Once u and its gradient are found through a numerical approximation, they can be used to obtain the optimal control
in feedback form: d∗ = d(q, p).
7
Subfigure Policy Total time Time till switching (denoted by *) Overall cost
(a) “treat immediately but not long enough” 18.32 1.7 +∞
(b) “start treating after 10 time steps” 10.73 10 2.29
(c) “MTD-based” 1.81 — 5.45
(d) “optimal” 11.56 10.86 2.25
Figure 2: The importance of optimal scheduling for drug therapy: ensuring recovery and decreasing the cost
of treatment.
Tumor evolution under four different treatment strategies for the same initial state (xD, xG, xV ) = (0.04, 0.9, 0.06). A seemingly
reasonable treatment strategy may not lead to a recovery; see subfigure (d). Even if a patient eventually recovers (as in
subfigures (b) and (c), the overall cost of treatment can be reduced by pursuing a provably optimal policy (d).
Top row: tumor evolutionary trajectories under different strategies on a GLY-VOP-DEF triangle. Green part of a trajectory
– no therapy is used. Red part of a trajectory – MTD-based (standard) therapy. The moment of switching from one regime
to another is denoted by (red *). Dash light blue and gray lines separate the recovery zone and the failure zone respectively.
Black cross – termination due to crossing the failure or recovery barrier.
Bottom row: evolution of sub-populations with respect to time based on the reference trajectories above. Green time range
– no therapy. Pink time range – MTD-based therapy. Black cross – termination due to crossing the failure or recovery barrier
by GLY cells.
Parameters: Following Figure 2 in40 and Figure 1, we use the initial state (xD, xG, xV ) = (0.04, 0.9, 0.06); game parameters:
ba = 2.5, bv = 2, c = 1, n = 4; the MTD rate: dmax = 3; the recovery and failure barriers: rb = fb = 10
−1.5; and the
time-penalty: σ = 0.01.
The corresponding therapy on/off regions and the resulting vector field are shown in Figure 3(a). The zoomed
version shows that trajectories can be prevented from crossing the failure barrier by using the MTDs just before
crossing. In fact, a chattering control (with intermittent and sufficiently frequent use of MTDs) would be sufficient
to guarantee this.
The level sets of u in Figure 3(b) show that value functions need not be smooth. Since the gradient of u is used
to determine the optimal course of action (therapy on or off), there can actually be more than one optimal policy
for initial states on a shockline (where that gradient is undefined). We show an example of such trajectories for
an initial point (xD, xG, xV ) ≈ (0.417, 0.311, 0.272) (solid green and red lines in Figure 3(b)). Both trajectories
yield the same cost of 2.764. Moreover, non-smoothness of the value function often poses a challenge for method’s
based on Pontryagin Maximum Principle (PMP)28 even if the initial state is not on a shockline. For example,
perturbing the initial state to a nearby (xD, xG, xV ) = (0.35, 0.3, 0.35), denoted by a cross in Figure 3(c), one sees
two locally optimal trajectories and PMP might yield either of these depending on the initial guess. The green one
is however inferior to the globally optimal red trajectory, which is always recovered by solving the HJB equation.
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(a) (b) (c)
Figure 3: Optimal control in feedback form, the value function, and the pitfalls of PMP.
(a): A phase portrait of the optimal system dynamics. The vector field is shown by gray arrows over the optimal drugs-off
(blue background) and drugs-on (yellow background) regions. A sample optimal trajectory (in green and red) corresponds to
the initial state from Figure 2.
(b): Computation of the value function u (whose level curves are shown by light blue lines) is used to determine the optimal
drugs-on and drugs-off regions (shown in yellow and dark blue respectively). Optimal trajectories are not unique for initial
states on the shockline (where the level curves of u are not smooth). Two such optimal trajectories are shown starting from
an asterisk (*).
The green-red trajectory takes longer to reach the recovery, but uses less drugs than the red (start-drugs-right-away) trajectory.
The cumulative cost is the same for both of them.
(c): For initial conditions off the shocklines of u, there can still be multiple locally optimal trajectories. We show an example
of two such trajectories starting from a cross marker (×). The risk of applying the PMP method is that it might yield either
of them, but only the red (start-drugs-right-away) is globally optimal.
Parameters: ba = 2.5, bv = 2, c = 1, n = 4, dmax = 3, σ = 0.01, rb = fb = 10
−1.5. Initial states of trajectories: (a)
(xD, xG, xV ) = (0.04, 0.9, 0.06); (b) denoted by (*) (xD, xG, xV ) = (0.417, 0.311, 0.272); (c) denoted by (×) (xD, xG, xV ) =
(0.35, 0.3, 0.35).
3.2 Optimization trade-offs: total administered drugs versus time to recovery
The optimal therapy-on regions are clearly dependent on specific values of all model parameters. Here we explore
their dependence on σ and dmax. Recall that, for every policy leading to recovery, the overall cost of treatment is a
sum of the “therapy cost” (i.e., the total amount of drugs administered, D =
T∫
0
d(t)dt) and the treatment-time cost
σT . Since the optimal control is bang-bang, this can be re-written as a weighted sum of the time-till-recovery T ,
and the total drug therapy time T˜ ≤ T . That is, for controls based on repeated therapy-off/MTD-level-therapy
switches, we can re-write the overall cost as J = dmaxT˜ + σT, with the ratio between the weights (σ/dmax)
representing the “relative importance” of T and T˜ for the optimization. But the functional role of these weights
is quite different: while σ can be chosen to reflect our preferences, the MTD-rate dmax is dictated by the medical
reality, which will be patient and drug specific. By varying dmax while keeping (σ/dmax) constant, we can study
the role played by the MTD-level in determining optimal policies under a fixed relative preference between the
objectives. In Figure 4 we conduct this experiment for two different initial states and the same set of game
parameters (ba = 2.5, bv = 2, c = 1, n = 4), demonstrating that the value of dmax strongly influences the optimal
policies and the shape of the “therapy-on” yellow regions.
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Parameters
Initial State (IS) #1 :
(xD, xG, xV ) = (0.04, 0.9, 0.06)
Initial State #2 :
(xD, xG, xV ) = (0.15, 0.5, 0.35)
σ dmax subfigure total time total drugs overall cost subfigure total time total drugs overall cost
0.0025 0.75 (a) 42.7519 2.0808 2.1877 (e) 33.9242 3.0750 3.1598
0.005 1.5 (b) 11.5998 2.1376 2.1956 (f) 33.1649 3.0254 3.1912
0.01 3 (c) 11.5649 2.1306 2.2463 (g) 2.8230 3.1241 3.1524
0.08 24 (d) 10.9820 2.1520 3.0306 (h) 1.8920 3.1490 3.3004
Figure 4: Varying the MTD level affects all optimal trajectories.
Here we illustrate a fixed σ/dmax ratio (with dmax increasing from left to right), which is equivalent to preserving the relevant
importance (trade-off) between the total therapy time T˜ and the total treatment time T. Nevertheless, the optimal drugs-on
regions (in yellow) vary since any changes in dmax also affect the dynamics of the system (7).
Parameters: ba = 2.5, bv = 2, c = 1, n = 4; rb = fb = 10
−1.5. Two initial states and the (σ, dmax) values are specified in the
table above.
On the other hand, for any fixed/biological dmax value, we can vary σ to study how the trade-off between
T˜ and T affects the optimization. This experiment is conducted for the same two initial states in Figure 5. As
we can see, smaller σ entails larger total time. Intuitively, this happens since it becomes “cheaper” to pause the
therapy until we reach a “better” state to administer the drugs. Larger σ leads to a shorter time-to-recovery T ,
but also an increase in the total amount of administered drugs D = dmaxT˜ and a larger therapy-on region (shown
in yellow) in the state space.
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Parameters
Initial State (IS) #1 :
(xD, xG, xV ) = (0.04, 0.9, 0.06)
Initial State #2 :
(xD, xG, xV ) = (0.15, 0.5, 0.35)
σ dmax subfigure total time total drugs overall cost subfigure total time total drugs overall cost
0.00125 3 (a) 11.6363 2.1004 2.1447 (d) 34.4945 3.0713 3.1144
0.01 3 (b) 11.5649 2.1306 2.2463 (e) 2.8230 3.1241 3.1524
0.08 3 (c) 10.9897 2.1574 3.0366 (f) 1.9470 3.1648 3.3206
Figure 5: Different trade-offs (time to recovery vs total drugs) yield different optimal trajectories.
The MTD-rate dmax is fixed while σ increasing from left to right. The ratio (σ/dmax) defines the relevant importance of the
total amount of drugs (therapy cost) d versus the total treatment time T . An increase in σ results in smaller T and larger d
along the optimal trajectories.
Parameters: ba = 2.5, bv = 2, c = 1, n = 4; rb = fb = 10
−1.5.
3.3 “Incurable” states and periodic trajectories under MTD treatment.
One might think that, despite being sub-optimal, an aggressive MTD-based strategy is at least always fully reliable
and the resulting trajectories are guaranteed to reach the recovery zone from every initial configuration, as shown
in Figure 2(c). Indeed, if
ba
n+1
≤ dmax, the MDT-based policy (d(t) ≡ dmax) guarantees that p˙ is always negative;
see equation (7). But with
ba
n+1
> dmax the recovery might not be attained with the constant use of MTDs (even
if some other treatment policies are successful!).
Consider, for example, the following set of parameters: ba = 4, bv = 2, c = 1, n = 4; rb = fb = 10
−1.5;
dmax = 0.3, σ = 0.03 and an initial state (xD, xG, xV ) = (0.02, 0.8, 0.18). Under these parameters the MTD-based
therapy has a periodic trajectory‡; see Figure 6(b). Since the treatment time is infinite, the cost (10) of such
a policy is +∞. (In reality this would lead to the emergence of drug resistance and eventual failure, but this
biological situation is not modeled in Kaznatcheev et al.40.)
We can see that neither of two extreme strategies (“no-drugs-at-all” in Figure 6(a) and the MTD-based “drugs-
all-the-time” in Figure 6(b)) can bring the trajectory to the recovery zone. However, their adaptive combination
‡This is easy to prove by redefining the parameter ba := ba − (n + 1)dmax > 0 and reducing the MTD-based case to the periodic
behavior of the original uncontrolled system (3) in the parameter regime (4).
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can still achieve the objective. We show a trajectory corresponding to the optimal policy in Figure 6(c). With
a larger failure zone (e.g., rb = fb = 10
−1), a previously successful MTD-based treatment might even result in
death (Figure 6(d)), while the adaptive strategy still leads to recovery (Figure 6(e)).
For a fixed treatment policy, we define its corresponding “incurable” area to be a set of states starting from
which it is impossible to cross the recovery barrier. For example in Figure 6, the incurable area of the MTD-based
policy includes the state (xD, xG, xV ) = (0.02, 0.8, 0.18) (when rb = fb = 10
−1.5 or rb = fb = 10
−1). However,
this state is not in the (dramatically smaller) incurable area of the adaptive/optimal policy; see Figure 7.
Starting from any incurable configuration, one could similarly pose a different control problem of maximizing
the time until crossing the failure barrier. While we do not address it here, we note that the HJB approach would
be quite suitable to find optimal treatment policies for this problem as well.
Figure 6: MTD-based policy versus the optimal (adaptive) policy when the MTD rate is low (dmax <
ba
n+1
).
Top row: trajectories under both (a) “no therapy” policy and (b) the MTD-based policy are cyclic and cannot cross either
the recovery nor the failure barrier from the initial state denoted by (*). Nevertheless, the adaptive/optimal switching leads
to a full recovery (c).
Bottom row: With a larger failure zone, an MTD-based policy leads to patient’s putative death (d) even though it is still
possible to cross the recovery barrier under an adaptive/optimal policy (e).
Parameters: ba = 4, bv = 2, c = 1, n = 4; dmax = 0.3, σ = 0.03 and the initial state (*) (xD, xG, xV ) = (0.02, 0.8, 0.18). Top
row rb = fb = 10
−1.5, bottom row rb = fb = 10
−1.
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Figure 7: Comparison of the “incurable” area for the MTD-based policy versus the adaptive policy.
Using adaptive strategies even with small MTD the patient can recover from most of the states that is impossible using
MTD-based policy. The blue color indicates initial states from which the corresponding trajectories are able to achieve the
recovery zone; the green color represents states from which recovery is impossible (“incurable” area): the light green color
– trajectories eventually get into the failure zone; the dark green color – trajectories are cyclic and cannot cross either the
recovery or failure zones.
Parameters: ba = 4, bv = 2, c = 1, n = 4; dmax = 0.3.
Of course, the “incurable areas” are highly dependent on model parameters. In section 6.4 of Supplementary
Materials, we show that they can grow due to an increase in the MTD rate dmax or a decrease in vascularization
benefits bv.
4 Discussion
By now it is widely accepted that cancer is an evolutionary process, and that variation and selection drive the
emergence of drug resistance. While this new knowledge is driving cancer research forward, it has largely not
yet affected clinical practice, with the majority of clinical protocols relying on MTD-based approaches, which
invariably fail in the setting of most metastatic disease. This is changing with the advent of adaptive therapy –
therapeutic strategies specifically designed with a changing regimen prescribed: one that adapts to an evolving
tumor42.
To optimally design AT protocols, the underling dynamics of the tumor growth and treatment response must
be known. While the methods of learning these dynamics are still in their infancy, the last decade has seen a
flurry of activity using evolutionary game theory and other evolutionary models for a range of prescribed dynamics.
These works have shown qualitative changes in tumor behavior in a range of treatment scenarios, and importantly,
demonstrated that the order43, sequence40 and timing17 of therapy can drastically change the outcomes. As we
come closer to the reality of evolutionarily designed therapeutic trials in the mainstream, it is important then
that we develop methods not just to make our outcomes better, but also to formally optimize them.
However, before using the mathematical tools for optimization, one also needs to choose a specific quantifiable
criterion for comparing the outcomes. Once that criterion is selected and the underlying mathematical model is
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sufficiently accurate, the best treatment strategy can be found by the techniques of optimal control theory. In
this paper, we show how this can be done for one particular heterogeneous cancer model previously described
in Kaznatcheev et al.40. Given a set of model parameters (bv, ba, c, n) and treatment/recovery parameters
(dmax, rb, fb), we can find an optimal treatment policy for any initial distribution of cells (q0, p0). We show
that the optimal treatment policy can have multiple regimes: always on d∗(·) ≡ dmax, always off d∗(·) ≡ 0, and
involving several contiguous treatment periods. For the latter, the challenge is to accurately approximate the
on/off “switching curves” in the state space. We show that the definition of optimal treatment policy is heavily
dependent on a parameter σ, a “cost” term, describing the relative importance of minimizing the total amount
of drugs administered versus the total time to recovery. We further show that, for some parameter regimes, there
are “incurable regions” in the state space – the starting configurations that will not lead to a recovery regardless
of the chosen treatment strategy – suggesting an alternative therapy (or goal) should be considered. Moreover,
for some other starting configurations, the “always on” strategy might not lead to a recovery even if the recovery
is actually achievable with some on/off hybrid strategies.
Just as any other model, the approach in Kaznatcheev et al.40 is based on simplifying assumptions (e.g., only
the subpopulation fractions are important, and no novel types can arise), which limit its practical applicability. But
our message is broader, and we use this specific model primarily to illustrate the general optimization approach.
With adaptive therapy trials now under way showing early promise14, we propose that such methods will become
increasingly integrated into trial design discussions, with increasingly detailed cancer evolution equations or even
in data-driven/equation-free framework.
Of the two main approaches of optimal control theory, the Pontryagin Maximum Principle (PMP) has been
much more widely used in cancer treatment research up till now. In contrast, our approach here is based on
dynamic programming and the numerical methods for Hamilton-Jacobi-Bellman (HJB) equations. The higher
computational cost of these methods is balanced by several important practical considerations. First, they yield
a policy in feedback-form and are thus more robust to modeling/measurement errors. Second, they always return
the globally optimal treatment strategies and avoid some of the pitfalls well-know for the PMP-based methods
(e.g., see Figure 3(b)). With the advent of efficient numerical methods, we posit that the HJB equations will be
soon playing a larger role in treatment optimization.
There are several obvious directions for extending our approach. First, the ability to optimize outcomes
for a range of criteria will open new avenues to quantify physician/patient discussions concerning trade-offs
and personalized therapy that have previously been only qualitative. In the current paper, computing optimal
policies for different values of σ can be viewed as a small step in this direction. But there are many other
possible optimization criteria of practical interest. Methods for approximating all Pareto-optimal policies are
available44 but are usually more computationally challenging. For probabilistic cancer evolution models, one can
also choose between optimizing different characteristics of the same random quantity. (E.g., minimize the average
time-to-recovery versus maximizing the probability of recovery in the next year). Finally, one can also use the
choice of criterion to promote robustness by systematically treating possible measurement/modeling errors as
perturbations chosen by some adversarial player. Such “games-against-nature”, as described recently by Stankova
and colleagues42, can be similarly treated by solving Hamilton-Jacobi-Isaacs equations.
Another important limitation of the above techniques is our assumed full knowledge of the system state. E.g.,
we assumed that the exact subpopulation fractions are known at every point in time and can be used to decide
whether to administer the drugs. In practice, one can periodically obtain an approximation of these quantities
(e.g., based on a repeat biopsy), but most of the time the decisions must be made based on some less invasive
measurements (e.g., based on PSA-levels in castrate-resistant prostate cancer model14 or in cell free circulating
DNA as recently shown by Khan and colleagues45). A rigorous treatment of such optimization challenges will
require the framework of partially-observable controlled processes; see e.g., Davis and Varaiya46.
With cancer evolution playing a larger and larger role in our thinking about therapy, and adaptive/evolutionary
therapy coming to the fore, methods for optimizing these approaches will grow in importance. We suggest that
the HJB method be used in these scenarios, and that clinicians and modelers begin discussions of further method
development along these lines.
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6 Supplementary Materials
6.1 Deriving a Hamilton-Jacobi-Bellman equation
We start by explaining the logic of dynamic programming that yields the HJB PDE (12) (Box 3, Section 3.1),
and the “bang-bang” property of optimal treatment policies.
Recall that the evolving composition of cancer sub-populations can be fully defined by (q(t), p(t)); see formulas
(2) and (7). The process is tracked until we cross either a recovery or failure barrier; i.e., until the trajectory leaves
Ω =
(
[0, 1]× [0, 1]
)
\∆, with the terminal set ∆ defined in formula (6). For an arbitrary initial state (q0, p0) ∈ Ω,
the goal is to choose our treatment policy to minimize the integral of an instantaneous cost K(d(t)) = d(t) + σ
up to the terminal time T = T (q0, p0, d(·)). I.e., the total cost of starting at (q0, p0) and using a policy d(·) is
J(q0, p0, d(·)) =
T∫
0
K (d(s)) ds + g
(
q
(
T
)
, p
(
T
))
,
where g is the terminal cost specified on ∆ in formula (9). The value function u(q0, p0) is the result of minimizing
J over all available treatment policies, and we say that the policy d∗(·) is optimal if u(q0, p0) = J(q0, p0, d∗(·)).
Bellman’s Optimality Principle47 is the key idea of dynamic programming. It states that, if we move along any
optimal trajectory, a remaining (yet to be traversed) part of that trajectory is in itself optimal from our current
configuration/state. In terms of the above model,
u(q0, p0) =
τ∫
0
K (d∗(t)) ds + u
(
q(τ), p(τ)
)
(14)
should hold for every sufficiently small τ > 0. Assuming that the value function u(q, p) and d∗(t) are smooth, one
can use Taylor series and take the limit τ → 0 to obtain
∇u(q0, p0) ·
(
q˙(q0, p0, d
∗
0)
p˙(q0, p0, d
∗
0)
)
+ d∗0 + σ = 0. (15)
Here d∗0 = d
∗(0) is the optimal initial rate of therapy starting from (q0, p0) and (q˙, p˙) are specified by the right hand
side of the ODEs in (7). Since (15) does not involve d∗(t) for any t > 0, it is now natural to switch to a feedback
control perspective based on a state-dependent (rather than explicitly time-dependent) optimal control d∗0(q, p).
Since the latter is a priori unknown, a Hamilton-Jacobi PDE (12) is obtained by minimizing over all available
control values d ∈ [0, dmax] and demanding that (15) should hold at every (q, p) ∈ Ω. Additional boundary
conditions u = g are specified on ∆ by (13).
The above derivation is merely formal since the value function u is typically non-smooth. Indeed, (12) rarely
has classical solutions, and if one considers Lipschitz-continuous weak solutions (by demanding that the PDE
should hold wherever ∇u is defined), one immediately loses the uniqueness. Additional test conditions introduced
by Crandall and Lions48 are employed to pick out a viscosity solution – the unique weak solution coinciding with
the value function of the original control problem36. Convergence to this viscosity solution is also a requirement
for all numerical methods for HJB equations used in control-theoretic applications.
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Using the dynamics (7) specific to our model, the HJB equation (12) can be re-written as follows:
min
d∈[0,dmax]
{ [
1− upp(1− p)
]
d + uqq(1− q)
( bv
n+ 1
n∑
k=0
pk − c
)
+ upp(1− p)
( ba
n+ 1
− q(bv − c)
)
+ σ
}
= 0.
(16)
The linear d-dependence of the minimized expression allows us to find the minimizer in closed form:
d∗ =
{
dmax, if
(
1− upp(1− p)
)
< 0;
0, otherwise.
(17)
Therefore, an optimal treatment policy takes only extreme values – either 0 or dmax. This is usually called the
bang-bang property.
Using (17) in practice would require knowing up at every point (q, p). In principle up, can be computed
along an optimal trajectory (backwards, from the recovery barrier to our initial state (q0, p0) without solving
the PDE on the entire Ω. This is in a sense the main idea of Pontryagin Maximum Principle (PMP)28. This
method will work (and will be much more computationally attractive) as long as u remains smooth along the
optimal trajectory. Unfortunately, the PMP has no way of identifying whether a backward-traced trajectory
passes through a shockline (where ∇u is undefined). In practice, this would result in obtaining locally (rather
than globally) optimal treatment policies; see the example in Figure 3c. We thus focus on solving the full HJB
equation, yielding a variational formula for d∗(q, p).
6.2 Numerical methods for the Hamilton-Jacobi-Bellman equation
We obtain an approximate solution to HJB equations on a regular triangulated mesh over the (xD, xG, xV ) space;
see Figure 8(b). Since at any moment of time xV (t) ≡ 1−xG(t)−xD(t), it is enough to consider an ODE system
for two sub-populations xD(t) and xG(t). To simplify the notation, we will write{
y˙(t) = f
(
y(t), d(t)
)
y(0) = x,
(18)
where y(t) = (xD(t), xG(t)), x = (xD(0), xG(0)) and f(·) denotes the right-hand side of (7) in (xD, xG) coordinates
using the transformation (2).
Our approximation scheme is based on a first-order accurate semi-Lagrangian discretization49. Starting at a
meshpoint x and using control d, we assume that the rate of change is constant for a small time τ , yielding a new
state
x˜d = x+ τf(x, d). (19)
Assuming that the running cost is also constant over that small time interval, one can rewrite Bellman’s optimality
principle as
u(x) = min
d
{τK(d) + u (x˜d)} + o(τ). (20)
Since x˜d is usually not a meshpoint, u (x˜d) is approximated by interpolation using the neighboring meshpoint
values. (This is the key idea of all semi-Lagrangian techniques.) While there are many ways to choose τ, we
select it for each d value individually to guarantee that x˜d lies on a mesh line and only two neighboring values are
needed for the interpolation; a similar approach has been used in50,51. More specifically, suppose that a vector
f(x, d) anchored at x lies within a triangle xx1dx2d; see Figure 8(a). Then x˜d lies on a segment x1dx2d with
x˜d =
||x2d − x˜d||
||x1d − x2d||
x1d +
||x1d − x˜d||
||x1d − x2d||
x2d and τd =
||x− x˜d||
||f(x, d)|| .
Recalling that only extreme rates d can be optimal due to the bang-bang property, we obtain a coupled system
of discretized equations:
U(x) = min
d∈{0, dmax}
{ ||x− x˜d||
||f(x, d)||K(d) +
||x2d − x˜d||
||x1d − x2d||
U(x1d) +
||x1d − x˜d||
||x1d − x2d||
U(x2d)
}
, (21)
which must hold for each meshpoint x ∈ Ω. The boundary conditions are handled by setting U = 0 when xG < rb
and U = +∞ when xG > 1− fb.
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In our implementation, the above coupled system of discretized equations is handled by Gauss-Seidel iterations,
with an additional speed up through alternating meshpoint orderings (in a “Fast Sweeping” fashion)52–54. Another
alternative would be to decouple the system dynamically – by selecting larger τd adaptively so that “already
known” mesh values would be sufficient for updating the still-tentatively-known U values. The latter “Ordered
Upwind” approach has been primarily used in problems with geometric dynamics51,55,56 and offers advantages
when optimal trajectories frequently change directions. In the future, it would be interesting to extend it (as well
as its two-scale hybrids with sweeping57) to therapy optimization problems, particularly for the case of small σ.
(a) (b)
Figure 8: A Semi-Lagrangian scheme on a triangular mesh.
(a): A semi-Lagrangian discretization in (xD, xG).
(b): Linear transformation yields a regular triangular mesh.
From implementation purposes, it is easier to conduct computations in a Cartesian coordinate system (Figure
8(a)), which is equivalent to a regular triangular mesh (Figure 8(b)) by a linear transformation.
To ensure the accuracy of the value function in Figure 3(a), we have used n = 9000 meshpoints along one side
of the GLY-VOP-DEF triangle, yielding N = 37 988 686 meshpoints in Ω with rb = fb = 10
−1.5. The algorithm
terminates when the difference between value functions in sequential iterations falls below 10−5, which required
a total of 62 iterations (sweeps) for this example.
In the future, we hope to reduce the computational cost by using a higher-order accurate semi-Lagrangian
discretization49 on a coarser mesh, employing “Ordered Upwind” techniques to reduce or eliminate the coupling
in the discretized system.
6.3 Fully angiogenic and glycolyctic tumors
In section 3 we have focused on optimizing treatment policies for polyclonal tumors. Under “therapy-off” policy
any trajectory of a polyclonal tumour has periodic dynamics and model parameters satisfy (4). Two other types
of tumours are also possible under the model40: fully angiogenic and fully glycolyctic.
A tumor has a fully angiogenic regime if max
(
ba
n+1
, cn
)
< bv − c. If the model (3) satisfies this condition all
cells tend to switch to VOP type and the trajectory converges to the recovery zone40. In some sense, the fully
angiogenic regime is less interesting case for our analysis because even without any therapy a patient will recover.
However, the optimal control analysis still might be useful when, for example, time-penalty is high (a patient
wants to recover as soon as possible) and some amount of drugs can be applied to accelerate the recovery, see
Figure 9(a).
A tumor has a fully glycolyctic regime if
ba
n+1
> bv − c, all cells tend to be GLY type cells and trajectories
converge to the failure zone from any initial state. Even if a treatment policy gives some short-term results, the
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trajectory will turn towards the failure zone once the therapy is stopped. Nevertheless, crossing the recovery
barrier means full recovery under assumptions of the model40. We consider an example of optimal policy for fully
glycolyctic tumour in Figure 9(b).
(a) (b)
Figure 9: The benefits of optimization in fully angiogenic and glycolyctic cases.
(a): two trajectories under AT strategy in a fully angiogenic tumour. Parameters: ba = 2, bv = 3, c = 1, n = 1; dmax = 3,
σ = 0.3, rb = fb = 10
−1.5.
(b): a trajectory under AT strategies in a fully glycolyctic tumour. Parameters: ba = 30, bv = 6, c = 1, n = 4; dmax = 3,
σ = 0.01, rb = fb = 10
−1.5.
6.4 Incurable areas changing under parameter variation
In Figure 10 we examine the changes in the optimal/minimal incurable area due to variations in the MTD rate
and model parameters.
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(a) (b) (c)
(d) (e) (f)
Subfigure
Parameters
dmax σ ba bv
(a) 0.3 0.03 4 2
(b) 0.2 0.03 4 2
(c) 0.1 0.03 4 2
(d) 0.2 0.01 2.5 2
(e) 0.2 0.01 2.5 1.8
(f) 0.2 0.01 2.5 1.6
Figure 10: Optimal drugs-on regions (in yellow) and incurable areas (in green) changing under parameter
variation.
“Incurable” areas can grow due to a decrease in the MTD rate dmax (top row) or a decrease in vascularization benefits bv
(bottom row). Common parameters for the figures: c = 1, n = 4, rb = fb = 10
−1.5.
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